RSC 1255
Alternative Names: RSC-1255Latest Information Update: 28 Mar 2024
At a glance
- Originator RasCal Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Ras gene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 16 Feb 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04678648)
- 28 Dec 2020 RasCal Therapeutics plans a phase Ia/Ib RSC-101 trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US (PO) (NCT04678648 )